drugset / Trial / NCT04878406

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

NCT04878406

Phase 1 Completed 24 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study looks at how the new medicine called NNC0480-0389 works in the body of Japanese men when it is given together with semaglutide. Participants will get NNC0480-0389 and semaglutide or 2 doses of placebo - which treatment participants get is decided by chance. NNC0480-0389 is a new medicine that has not been previously approved. It means that the medicine has not yet been approved by the health authorities. Semaglutide is a newly approved antidiabetic medicine that helps to lower blood sugar levels in patients with type 2 diabetes. NNC0480-0389 is being developed to be given together with semaglutide.NNC0480-0389 targets a different part of the system that regulates sugar levels in the body than semaglutide. Therefore, it is expected that together NNC0480-0389 and semaglutide will more effectively lower sugar levels in the blood. Participants will get 2 injections of the study medicine. It will be injected with a needle into a skin fold on participants' stomach. The study will last for a maximum of 72 days. Participants will have 10 scheduled visits with the study doctor. For 1 of the visits participants will stay at the clinic for 6 days (5 nights).The study includes blood sampling.

Timeline

Start
2021-05-18
Primary completion
2021-07-20
Completion
2021-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject NNC0480-0389 Unknown 1.7 mg Subcutaneous
Subject NNC0480-0389 Unknown 8.6 mg Subcutaneous
Subject NNC0480-0389 Unknown 30 mg Subcutaneous
Subject Semaglutide Peptide 0.5 mg Subcutaneous

Indications

No indication recorded.